Challenge: An Argus Safety validation with no internal lead
A global biotech company required initial validation of a new Argus Safety database, along with a migration of pharmacovigilance data from a legacy database. Two factors made the effort complex. First, the company did not have an internal validation lead to oversee the validation process for Argus. Second, the project required special expertise in transferring Argus data out of a legacy organization, adding risk to an already demanding implementation.
With a post-implementation FDA audit on the horizon, the company needed both a system it could trust and the documented evidence to prove it — the kind of 21 CFR Part 11 compliance and data integrity rigor that inspectors expect from a safety system.
Approach: Validation leadership plus a defensible data migration
To address their needs, the company engaged USDM Life Sciences (USDM) to handle the validation and data migration tasks. USDM stepped into the validation lead role the company lacked, owning the validation process for Argus from planning through execution.
USDM developed a Validation Master Plan to ensure the new Argus Safety database met Good Documentation Practices and data integrity principles. A modern, risk-based mindset — consistent with computer software assurance (CSA) — kept validation effort focused where it mattered most to patient safety and regulatory risk.
Migrating legacy safety data without losing fidelity
Transferring Argus data from the legacy organization demanded specialized expertise. Despite the challenges, the legacy data was successfully transferred to the new database, minimizing the risk of data loss and discrepancies. The migration was treated as a controlled, evidence-producing activity so the resulting records would stand up to scrutiny under the same data integrity in life sciences standards applied to the rest of the system.
Results: Confident, audit-ready, and compliant
Working with USDM, the company was well prepared for its post-implementation audit by the FDA.
- Legacy data fully migrated to the new Argus Safety database, minimizing the risk of data loss and discrepancies.
- The missing validation lead role filled by USDM, giving the project the oversight it needed end to end.
- A Validation Master Plan that met Good Documentation Practices and data integrity principles, providing the documented evidence an FDA inspection requires.
This successful project allowed the company to confidently move forward, knowing they were fully prepared to navigate the complex regulatory landscape. With validation and data integrity established as an ongoing discipline rather than a one-time event, the company is positioned to sustain its compliant state through continuous compliance as its safety operations evolve.